IN THE SPOTLIGHT

IMFINZI® (durvalumab) is the first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placebo

IMFINZI® (durvalumab) is the first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placebo

ASCO: AstraZeneca's Tagrisso, Imfinzi break new grounds in lung cancer—with one standing ovation

ASCO: AstraZeneca's Tagrisso, Imfinzi break new grounds in lung cancer—with one standing ovation

FDA approves Imdelltra for patients with extensive-stage small cell lung cancer

FDA approves Imdelltra for patients with extensive-stage small cell lung cancer

Amgen Drug for Aggressive Type of Lung Cancer Wins Accelerated FDA Approval

Amgen Drug for Aggressive Type of Lung Cancer Wins Accelerated FDA Approval

FDA approves Amgen T-cell engager for small cell lung cancer

FDA approves Amgen T-cell engager for small cell lung cancer

Amgen Wins FDA Approval for Difficult-to-Treat Lung Cancer

Amgen Wins FDA Approval for Difficult-to-Treat Lung Cancer

FDA approves Imdelltra for small cell lung cancer

FDA approves Imdelltra for small cell lung cancer

Possible Therapeutic Target Identified for Small Cell Lung Cancer

Possible Therapeutic Target Identified for Small Cell Lung Cancer

Durvalumab Shows Improvements in Overall Survival, Progression-Free Survival for Small Cell Lung Cancer

Durvalumab Shows Improvements in Overall Survival, Progression-Free Survival for Small Cell Lung Cancer

Treating Women With Lung Cancer: Screening, Treatment, and Sexual and Reproductive Health

Treating Women With Lung Cancer: Screening, Treatment, and Sexual and Reproductive Health